By Ben Butkus

Great Basin has commenced a clinical trial to evaluate its first molecular diagnostic test, an assay for Clostridium difficile using the company's cartridge-based sample-to-answer molecular testing platform

The company also said that it has achieved encouraging results in a preclinical study of the C. difficile assay, and that if clinical trial results are equally positive the company plans to submit the test for US Food and Drug Administration approval by the end of the summer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.